JPH08509705A - Rxrレチノイドレセプター作働剤活性を有する化合物による腫瘍の処置 - Google Patents
Rxrレチノイドレセプター作働剤活性を有する化合物による腫瘍の処置Info
- Publication number
- JPH08509705A JPH08509705A JP6520298A JP52029894A JPH08509705A JP H08509705 A JPH08509705 A JP H08509705A JP 6520298 A JP6520298 A JP 6520298A JP 52029894 A JP52029894 A JP 52029894A JP H08509705 A JPH08509705 A JP H08509705A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- active compound
- lower alkyl
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.レチノイド様活性を有し、RXRレチノイドレセプター作働剤である活性 化合物の有効量を含有する薬剤組成物を、腫瘍を有するヒトを包含する哺乳動物 に、腫瘍細胞のアポプトシスを誘導し、それにより腫瘍を処置する目的で投与す る方法。 2.活性化合物は、RARレチノイドレセプターよりもRXRレチノイドレセ プターに選択的な作働剤である請求項1記載の方法。 3.活性化合物は、RARレチノイドレセプターと比較してRXRレチノイド レセプターに特異的な作働剤である請求項1記載の方法。 4.哺乳動物に、1日当たり約0.01〜100mg/kg体重の活性化合物を投 与する請求項1記載の方法。 5.哺乳動物に、1日当たり約0.1〜10mg/kg体重の活性化合物を全身的 に投与する請求項4記載の方法。 6.活性化合物は下記式で示される請求項1記載の方法: [式中、 R1は低級アルキル、Cl、BrまたはIであり; R2はH、低級アルキル、Cl、BrまたはIであり; R3は低級アルキル、Cl、Br、I、OR11、SR11、OCOR11、SCOR1 1 、NH2、NHR11、N(R11)2、NHCOR11またはNR11−COR11であり ; R5はそれぞれH、低級アルキル、Cl、Br、I、低級アルコキシまたは低級 チオアルコキシ(炭素数1〜6)であり; R6はそれぞれ、Hまたは低級アルキルであり; Aは(CH2)n(nは0〜5)、炭素数3〜6の低級分枝鎖アルキル、炭素数 3〜6のシクロアルキル、炭素数2〜6/二重結合数1または2のアルケニル、 炭素数2〜6/三重結合数1または2のアルキニルであり; Bは水素、COOHもしくは薬学的に許容し得るその塩、COOR8、CON R9R10、−CH2OH、CH2OR11、CH2OCOR11、CHO、CH(OR12 )2、CHOR13O、−COR7、CR7(OR12)2、またはCR7OR13Oであ り、R7は炭素数1〜5のアルキル、シクロアルキルまたはアルケニルであり、 R8は炭素数1〜10のアルキル、炭素数5〜10のシクロアルキル、フェニル または低級アルキルフェニルであり、R9およびR10はそれぞれ水素、炭素数1 〜10のアルキル、炭素数5〜10のシクロアルキル、フェニルまたは低級アル キルフェニルであり、R11は炭素数1〜10のアルキル、フェニルまたは低級ア ルキルフェニルであり、R12は低級アルキルであり、R13は炭素数2〜5の2価 アルキルである。]。 7.活性化合物の式において、R1、R3およびR6はメチルであり、RRおよび R5は水素であり、−A−BはCOOR8である請求項6記載の方法。 8.R8は水素である請求項7記載の方法。 9.COOR8基はチオフェン環の4位に存在する請求項8記載の方法。 10.COOR8基はチオフェン環の5位に存在する請求項8記載の方法。 11.レチノイド様生物学的活性を有する活性化合物の有効量を含有する薬剤 組成物を、腫瘍を有するヒトを包含する哺乳動物に、腫瘍細胞のアポプトシスを 誘導し、それにより腫瘍を処置する目的で投与する方法であって、該化合物は、 RXRレセプターへの結合を4−(E)−2−(5,6,7,8−テトラヒドロ− 3,5,5,8,8−ペンタメチルナフタレン−2−イル)プロペン−1−イル]安 息香酸と比較するアッセイにおいて示されるように[該アッセイにおいて、前記 活性化合物も、4−(E)−2−(5,6,7,8−テトラヒドロ−3,5,5,8, 8−ペンタメチルナフタレン−2−イル)プロペン−1−イル]安息香酸も、R XRレセプターの作働剤として作用する]、RXRレチノイドレセプター作働剤 であるとい う生物学的性質を有する方法。 12.哺乳動物に、1日当たり約0.01〜100mg/kg体重の活性化合物を 全身的に投与する請求項11記載の方法。 13.哺乳動物に、1日当たり約0.1〜10mg/kg体重の活性化合物を全身 的に投与する請求項12記載の方法。 14.活性化合物は、RARレセプターに対する結合をトランスレチノイン酸 と比較するアッセイにおいて、RARレセプター作働剤として顕著な活性を示さ ないという生物学的性質をも有する請求項12記載の方法。 15.腫瘍を有する哺乳動物において腫瘍細胞のアポプトシスを誘導するのに 適当な薬剤組成物であって、薬学的に許容し得る賦形剤、およびRXRレチノイ ドレセプター作働剤であるという生物学的性質を有する活性化合物を含有する薬 剤組成物。 16.活性化合物の濃度は、約0.001〜5重量%である請求項15記載の 薬剤組成物。 17.活性化合物は、RARレチノイドレセプターと比較してRXRレチノイ ドレセプターに特異的な作働剤である請求項15記載の薬剤組成物。 18.活性化合物は下記式で示される請求項15記載の薬剤組成物: [式中、 R1は低級アルキル、Cl、BrまたはIであり; R2はH、低級アルキル、Cl、BrまたはIであり; R3は低級アルキル、Cl、Br、I、OR11、SR11、OCOR11、SCOR1 1 、NH2、NHR11、N(R11)2、NHCOR11またはNR11−COR11であ り; R5はそれぞれH、低級アルキルCl,Br,I低級アルコキシまたは低級チオ アルコキシ(炭素数1〜6)であり; R6はそれぞれ、Hまたは低級アルキルであり; Aは(CH2)n(nは0〜5)、炭素数3〜6の低級分枝鎖アルキル、炭素数 3〜6のシクロアルキル、炭素数2〜6/二重結合数1または2のアルケニル、 炭素数2〜6/三重結合数1または2のアルキニルであり; Bは水素、COOHもしくは薬学的に許容し得るその塩、COOR8、CON R9R10、−CH2OH、CH2OR11、CH2OCOR11、CHO、CH(OR12 )2、CHOR13O、−COR7、CR7(OR12)2、またはCR7OR13Oであ り、R7は炭素数1〜5のアルキル、シクロアルキルまたはアルケニルであり、 R8は炭素数1〜10のアルキル、炭素数5〜10のシクロアルキル、フェニル または低級アルキルフェニルであり、R9およびR10はそれぞれ水素、炭素数1 〜10のアルキル、炭素数5〜10のシクロアルキル、フェニルまたは低級アル キルフェニルであり、R11は炭素数1〜10のアルキル、フェニルまたは低級ア ルキルフェニルであり、R12は低級アルキルであり、R13は炭素数2〜5の2価 アルキルである。]。 19.活性化合物の式において、R1、R3およびR8はメチルであり、R2およ びR5は水素であり、−A−BはCOOR8である請求項18記載の薬剤組成物。 20.R8は水素である請求項19記載の薬剤組成物。 21.COOR8基はチオフェン環の4位に存在する請求項20記載の薬剤組 成物。 22.COOR8基はチオフェン環の5位に存在する請求項20記載の薬剤組 成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/029,801 | 1993-03-11 | ||
US08/029,801 US5399586A (en) | 1993-03-11 | 1993-03-11 | Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity |
PCT/US1994/002577 WO1994020093A1 (en) | 1993-03-11 | 1994-03-10 | Treatment of tumors with compounds having rxr retinoid receptor agonist activity |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH08509705A true JPH08509705A (ja) | 1996-10-15 |
Family
ID=21850946
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP6520298A Ceased JPH08509705A (ja) | 1993-03-11 | 1994-03-10 | Rxrレチノイドレセプター作働剤活性を有する化合物による腫瘍の処置 |
Country Status (9)
Country | Link |
---|---|
US (1) | US5399586A (ja) |
EP (3) | EP0909560A3 (ja) |
JP (1) | JPH08509705A (ja) |
CN (1) | CN1080117C (ja) |
AT (1) | ATE210440T1 (ja) |
AU (1) | AU678823B2 (ja) |
CA (1) | CA2157798A1 (ja) |
DE (1) | DE69429427T2 (ja) |
WO (1) | WO1994020093A1 (ja) |
Families Citing this family (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5264578A (en) * | 1987-03-20 | 1993-11-23 | Allergan, Inc. | Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity |
US5183827A (en) * | 1989-09-19 | 1993-02-02 | Allergan, Inc. | Acetylenes disubstituted with a heteroaromatic group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity |
US5272156A (en) * | 1989-09-19 | 1993-12-21 | Allergan, Inc. | Acetylenes disubstituted with a heteroaromatic group and a 2-substituted 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity |
US5264456A (en) * | 1989-12-29 | 1993-11-23 | Allergan, Inc. | Acetylenes disubstituted with a furyl group and a substituted phenyl group having retinoid like activity |
US5968989A (en) * | 1991-12-18 | 1999-10-19 | The Salk Institute For Biological Studies | Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor |
US7056954B2 (en) * | 1991-12-18 | 2006-06-06 | The Salk Institute For Biological Studies | Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor |
US5962731A (en) * | 1992-04-22 | 1999-10-05 | Ligand Pharmaceuticals Incorporated | Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors |
US5780676A (en) * | 1992-04-22 | 1998-07-14 | Ligand Pharmaceuticals Incorporated | Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors |
US7655699B1 (en) | 1992-04-22 | 2010-02-02 | Eisai Inc. | Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors |
US5455265A (en) | 1993-02-11 | 1995-10-03 | Allergan, Inc. | Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors |
US6172115B1 (en) | 1993-02-11 | 2001-01-09 | Allergan Sales, Inc. | Method for preventing onset of restenosis after angioplasty employing an RXR-specific retinoid |
DE4319506A1 (de) * | 1993-06-12 | 1994-12-15 | Boehringer Mannheim Gmbh | Verfahren zum Nachweis metabolisch markierter DNA |
US5475022A (en) * | 1993-10-18 | 1995-12-12 | Allergan, Inc. | Phenyl or heteroaryl and tetrahydronaphthyl substituted diene compounds having retinoid like biological activity |
US5426118A (en) * | 1993-12-30 | 1995-06-20 | Allergan, Inc. | [4-(1,2-epoxycyclohexanyl)but-3-en-1-ynyl]aromatic and heteroaromatic acids and derivatives having retinoid-like biological activity |
AU2604795A (en) * | 1994-05-26 | 1995-12-21 | New York Medical College | Detection of halogenated precursors incorporated into dna |
US5543534A (en) * | 1994-12-29 | 1996-08-06 | Allergan | Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl groups having retinoid-like biological activity |
US5618943A (en) * | 1994-12-29 | 1997-04-08 | Allergan | Acetylenes disubstituted with a 5 OXO substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity |
US5648514A (en) * | 1994-12-29 | 1997-07-15 | Allergan | Substituted acetylenes having retinoid-like biological activity |
US5599967A (en) * | 1994-12-29 | 1997-02-04 | Allergan | Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl of heteroaryl group having retinoid-like biological activity |
US5534641A (en) * | 1994-12-29 | 1996-07-09 | Allergan | Acetylenes disubstituted with 2-tetrahydropyranoxyaryl and aryl or heteroaryl groups having retinoid-like biological activity |
US5514825A (en) * | 1994-12-29 | 1996-05-07 | Allergan, Inc. | Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity |
EP0822811A1 (en) * | 1995-04-21 | 1998-02-11 | Ligand Pharmaceuticals, Inc. | Inhibition of apoptosis in cells expressing fas-ligand following activation |
US6025388A (en) * | 1995-04-26 | 2000-02-15 | Allergan Sales, Inc. | Method for inhibiting gene expression promoted by AP1 protein with RARβ selective retinoids and method for treatment of diseases and conditions with such retinoids |
US5616712A (en) * | 1995-05-16 | 1997-04-01 | Allergan | Acetylenes disubstituted with a phenyl or heteroaryl group and a 2-thio-1,2,3,4-tetrahdroquinolinyl, 2-alkylthio-3,4-dihydroquinolinyl or 2-alkoxy-3,4-dihydroquinolinyl group having retinoid-like biological activity |
US5917082A (en) * | 1995-06-06 | 1999-06-29 | Allergan Sales, Inc. | 2,4-pentadienoic acid derivatives having retinoid-like biological activity |
US5675033A (en) * | 1995-06-06 | 1997-10-07 | Allergan | 2,4-pentadienoic acid derivatives having retinoid-like biological activity |
FR2735370B1 (fr) * | 1995-06-19 | 1997-07-18 | Cird Galderma | Procede pour identifier des composes agonistes des recepteurs rxrs |
WO1997008345A1 (en) * | 1995-08-30 | 1997-03-06 | New York Medical College | Methods for labeling dna ends with halogenated nucleotides and detecting same with antibodies |
US5958954A (en) * | 1995-09-01 | 1999-09-28 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
US5952345A (en) * | 1995-09-01 | 1999-09-14 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
US6008204A (en) * | 1995-09-01 | 1999-12-28 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
US6942980B1 (en) | 1995-09-01 | 2005-09-13 | Allergan, Inc. | Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities |
US6218128B1 (en) | 1997-09-12 | 2001-04-17 | Allergan Sales, Inc. | Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities |
AU7074496A (en) | 1995-09-18 | 1997-04-09 | Ligand Pharmaceuticals Incorporated | Ppar gamma antagonists for treating obesity |
ES2190479T3 (es) | 1995-10-06 | 2003-08-01 | Ligand Pharm Inc | Moduladores de rxr selectivos a dimeros y metodos para su uso. |
FR2739777B1 (fr) * | 1995-10-11 | 1997-11-14 | Cird Galderma | Ligand antagoniste rar-gamma ou agoniste rar-alpha en tant qu'inhibiteur d'apoptose |
AU7598596A (en) * | 1995-11-01 | 1997-05-22 | Allergan, Inc. | Sulfides, sulfoxides and sulfones disubstituted with a tetrahydronaphthalenyl, chromanyl, thiochromanyl or tetrahydroquinolinyl and substituted phenyl or heteroaryl group, having retinoid-like biological activity |
US5675024A (en) * | 1995-11-22 | 1997-10-07 | Allergan | Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4,-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity |
US5663357A (en) * | 1995-11-22 | 1997-09-02 | Allergan | Substituted heteroarylamides having retinoid-like biological activity |
US5965606A (en) | 1995-12-29 | 1999-10-12 | Allergan Sales, Inc. | Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity |
US5688957A (en) * | 1995-12-29 | 1997-11-18 | Allergan | (3"-thioxacyclohex-1"-enyl)!-but-3'-ene-1'-ynyl!aryl and (3"-thioxacyclohex-1"-enyl)!-but-3'-ene-1'-ynyl!heteroaryl carboxylic acids and esters having retinoid-like biological activity |
US20030219832A1 (en) * | 1996-03-11 | 2003-11-27 | Klein Elliott S. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
US6406917B1 (en) | 1996-06-11 | 2002-06-18 | Advanced Research And Technology Institute | Methods and compositions for the use of apurinic/apyrimidinic endonucleases |
EP0923738A1 (en) * | 1996-06-11 | 1999-06-23 | Advanced Research & Technology Institute | Methods and compositions for the use of apurinic/apyrimidinic endonucleases |
US5741896A (en) | 1996-06-21 | 1998-04-21 | Allergan | O- or S- substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
US5747542A (en) * | 1996-06-21 | 1998-05-05 | Allergan | Oxo-substituted tetrahydronaphthalene derivatives having retinold and/or retinoid antagonist-like biological activity |
US5763635A (en) * | 1996-06-21 | 1998-06-09 | Allergan | Tetrahydronaphthalene derivatives substituted in the 8 position with alkyhidene groups having retinoid and/or retinoid antagonist-like biological activity |
US6555690B2 (en) | 1996-06-21 | 2003-04-29 | Allergan, Inc. | Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
US5808124A (en) * | 1996-06-21 | 1998-09-15 | Allergan | O- or S-substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
US5773594A (en) | 1996-06-21 | 1998-06-30 | Allergan | Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
US5723666A (en) * | 1996-06-21 | 1998-03-03 | Allergan | Oxime substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
US6130230A (en) * | 1996-08-28 | 2000-10-10 | Institut National De La Sante Et De La Recherche Medicale | Therapeutic combinations of RAR antagonists and RXR agonists and use thereof |
US20020151063A1 (en) * | 1996-08-30 | 2002-10-17 | Annette Lasham | Methods for modulating apoptotic cell death |
US5912168A (en) * | 1996-08-30 | 1999-06-15 | Genesis Research & Development Corporation Limited | CD95 regulatory gene sequences |
FR2752734B1 (fr) * | 1996-09-02 | 1998-11-06 | Cird Galderma | Utilisation de retinoides pour la preparation d'un medicament destine a traiter les affections liees a une surexpression de vegf |
US5739338A (en) * | 1996-11-05 | 1998-04-14 | Allergan | N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity |
US5728846A (en) * | 1996-12-12 | 1998-03-17 | Allergan | Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives |
EP0963199A1 (en) * | 1996-12-31 | 1999-12-15 | The Salk Institute For Biological Studies | Treatment of disease states which result from neoplastic cell proliferation using ppar-gamma activators and compositions useful therefor |
US5760276A (en) * | 1997-03-06 | 1998-06-02 | Allergan | Aryl-and heteroarylcyclohexenyl substituted alkenes having retinoid agonist, antagonist or inverse agonist type biological activity |
US6037488A (en) | 1997-04-19 | 2000-03-14 | Allergan Sales, Inc. | Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity |
AU744475B2 (en) | 1997-04-24 | 2002-02-28 | Bristol-Myers Squibb Company | Methods and compositions for use in modulating expression of matrix metalloproteinase genes |
US5919970A (en) | 1997-04-24 | 1999-07-06 | Allergan Sales, Inc. | Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity |
CA2295807A1 (en) * | 1997-07-29 | 1999-02-11 | Bristol-Myers Squibb Company | Use of selective rxr agonists to prevent surgical adhesions |
US6521814B1 (en) | 1997-12-22 | 2003-02-18 | Institut National De La Santa Et De La Recherche Medicale | Use of ligands for treatment of diseases responsive to retinoids |
EP1093362A1 (en) * | 1998-06-12 | 2001-04-25 | Ligand Pharmaceuticals Incorporated | Treatment of anti-estrogen resistant breast cancer using rxr modulators |
DK1520588T3 (en) | 1998-07-13 | 2015-03-23 | Univ Texas | Use of antibodies to aminophospholipids for cancer treatment |
EP1234585A3 (en) | 1998-09-04 | 2004-01-21 | The Regents Of The University Of Michigan | Methods and compositions for the prevention or treatment of cancer |
AU1740900A (en) * | 1998-11-20 | 2000-06-13 | Genentech Inc. | Method of inhibiting angiogenesis |
AU773928B2 (en) * | 1999-04-23 | 2004-06-10 | Bristol-Myers Squibb Company | Compositions and methods for treatment of hyperproliferative diseases |
US6624154B1 (en) * | 1999-04-23 | 2003-09-23 | Bristol-Myers Squibb Company | Compositions and methods for treatment of hyperproliferative diseases |
US20040228871A1 (en) * | 1999-06-03 | 2004-11-18 | Tayyaba Hasan | Treatment and analysis of proliferative disorders |
WO2001016133A2 (en) | 1999-08-27 | 2001-03-08 | Ligand Pharmaceuticals Incorporated | 8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators |
HUP0202814A3 (en) | 1999-08-27 | 2003-11-28 | Ligand Pharmaceuticals Inc San | Androgen receptor modulator compounds and methods for their preparation and pharmaceutical compositions containing them and their use |
US6566372B1 (en) | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
US6593493B1 (en) | 1999-09-14 | 2003-07-15 | Ligand Pharmaceuticals, Inc. | RXR modulators with improved pharmacologic profile |
DE122008000018I1 (de) | 2000-01-21 | 2008-08-14 | Novartis Pharma Ag | Zusammensetzungen bestehend aus Dipeptidylpeptidase-IV Inhibitoren und Antidiabetica |
US6355446B1 (en) * | 2000-03-24 | 2002-03-12 | Ludwig Institute For Cancer Research | DocosahexAenoic acid as retinoid X-receptor ligand and uses thereof |
US20020090352A1 (en) * | 2000-04-13 | 2002-07-11 | Frederick Geissmann | Compositions and methods for use in modulating immune system function |
US6403810B2 (en) * | 2000-07-10 | 2002-06-11 | Hoffmann-La Roche Inc. | Thiophene derivatives |
US20040143015A1 (en) * | 2001-03-12 | 2004-07-22 | Villhauer Edwin Bernard | Combination of organic compounds |
CA2438586A1 (en) * | 2001-03-14 | 2002-09-19 | Eli Lilly And Company | Retinoid x receptor modulators |
US7173134B2 (en) * | 2001-09-25 | 2007-02-06 | Smithkline Beecham Corporation | Selective RXR ligands |
AU2003223477A1 (en) * | 2002-04-05 | 2003-10-27 | University Of Utah Research Foundation | Regulation of a novel colon specific retinol dehydrogenase by apc and cdx2 |
EP1356820A1 (en) * | 2002-04-26 | 2003-10-29 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | DNA vaccine combined with an inducer of tumor cell apoptosis |
MX337052B (es) | 2002-07-15 | 2016-02-11 | Univ Texas | Peptidos que se enlazan a fosfatidiletanolamina y sus usos en el tratamiento de infecciones virales y del cancer. |
US8431396B2 (en) | 2003-03-21 | 2013-04-30 | The Cleveland Clinic Foundation | Anti-angiogenic peptides |
EP2390262A1 (en) | 2003-05-16 | 2011-11-30 | Intermune, Inc. | Synthetic chemokine receptor ligands and methods of use thereof |
US7407973B2 (en) * | 2003-10-24 | 2008-08-05 | Intermune, Inc. | Use of pirfenidone in therapeutic regimens |
MXPA06008293A (es) | 2004-01-22 | 2007-06-11 | Univ Miami | Formulaciones topicas de coenzima q10 y metodos de uso. |
US9050310B2 (en) | 2004-06-25 | 2015-06-09 | Minas Theodore Coroneo | Treatment of ocular lesions |
EP1978971A4 (en) * | 2005-12-30 | 2012-03-28 | Revance Therapeutics Inc | ARGININE HETEROMERS FOR TOPICAL HARVESTING |
WO2008020027A2 (en) | 2006-08-16 | 2008-02-21 | Action Medicines, S.L. | 2,5-dihydroxybenzene compounds for the treatment of skin cancer |
EP3181132A1 (en) * | 2007-01-15 | 2017-06-21 | Chongxi Yu | Positively charged water-soluble prodrugs of retinoids and retinoid-like compounds with very high skin penetration rates |
BRPI0820298A8 (pt) | 2007-11-09 | 2018-05-08 | Affitech Res As | composições e métodos de anticorpos anti-vegf |
WO2009102789A2 (en) * | 2008-02-15 | 2009-08-20 | Wyeth | Use of rxr agonists for the treatment of osteroarthritis |
US8772273B2 (en) * | 2011-10-04 | 2014-07-08 | Quretino Therapeutics, Inc. | Formulations and uses of retinoic acid receptor selective agonists |
WO2015059632A1 (en) | 2013-10-23 | 2015-04-30 | Acadia Pharmaceuticals Inc. | Treatment of a neurodegenerative disease or disorder |
US11045441B2 (en) | 2015-10-13 | 2021-06-29 | Wisconsin Alumni Research Foundation | Use of retinoic acid and analogs thereof to treat central neural apneas |
EP3833399A4 (en) * | 2018-08-10 | 2022-08-31 | Sanford Burnham Prebys Medical Discovery Institute | TUMOR ASSOCIATED MACROPHAGE BINDING MOLECULES AND METHODS OF USE |
US20230132366A9 (en) | 2018-11-26 | 2023-04-27 | Denali Therapeutics Inc. | Methods for treating dysregulated lipid metabolism |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4085091A (en) * | 1976-12-16 | 1978-04-18 | E. I. Dupont De Nemours And Company | Thermally stable, rigid polyesters from thermally stable, rigid dibasic acids and aromatic dihydroxy compounds |
US4326055A (en) * | 1977-12-22 | 1982-04-20 | Hoffmann-La Roche Inc. | Stilbene derivatives |
EP0047817A3 (de) * | 1980-08-14 | 1982-05-26 | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft | Hydrierte Naphthaline, deren Herstellung und Verwendung sowie derartige Naphthaline enthaltende Gemische |
DE3202118A1 (de) * | 1982-01-23 | 1983-07-28 | Basf Ag, 6700 Ludwigshafen | Substituierte vinylbenzoesaeure-derivate, ihre herstellung und diese enthaltende pharmazeutische zubereitungen |
EP0130795B1 (en) * | 1983-07-05 | 1988-11-23 | Pfizer Inc. | Carboxylic acid derivatives useful for inhibiting the degradation of cartilage |
DE3407510A1 (de) * | 1984-03-01 | 1985-09-05 | A. Nattermann & Cie GmbH, 5000 Köln | (omega)-aryl-alkylthienylalk(a,e)nsaeuren und ihre derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate |
JPS60222445A (ja) * | 1984-04-19 | 1985-11-07 | Yoshitomi Pharmaceut Ind Ltd | フタル酸化合物 |
JPS6122046A (ja) * | 1984-07-07 | 1986-01-30 | Koichi Shiyudo | スチルベン誘導体 |
LU85544A1 (fr) * | 1984-09-19 | 1986-04-03 | Cird | Derives heterocycliques aromatiques,leur procede de preparation et leur application dans les domaines therapeutique et cosmetique |
DE3434946A1 (de) * | 1984-09-22 | 1986-04-03 | Basf Ag, 6700 Ludwigshafen | Diarylacetylene, ihre herstellung und verwendung |
LU86022A1 (fr) * | 1985-07-25 | 1987-02-04 | Cird | Derives aromatiques polycyliques,leur procede de preparation et leur application dans les domaines pharmaceutique et cosmetique |
IL80270A0 (en) * | 1985-10-11 | 1987-01-30 | Cird | Naphthalene derivatives,their preparation and pharmaceutical compositions containing them |
LU86351A1 (fr) * | 1986-03-12 | 1987-11-11 | Oreal | Composes benzopyrannyl et benzothiopyrannyl benzoiques,leur procede de preparation et leur utilisation en cosmetique et en medecine humaine et veterinaire |
DE3615157A1 (de) * | 1986-05-05 | 1987-11-12 | Schwabe Willmar Gmbh & Co | 5-arylalkyl-4-alkoxy-2(5h)-furanone, zwischenprodukte und verfahren zu ihrer herstellung sowie ihre anwendung als therapeutische wirkstoffe |
ZW7487A1 (en) * | 1986-05-23 | 1987-12-16 | Hoffmann La Roche | Tetrahydronaphthaline and indane derivatives |
ZW10287A1 (en) * | 1986-07-15 | 1988-01-13 | Hoffmann La Roche | Tetrahydronaphthaline and indane derivatives |
US5084476A (en) * | 1986-07-15 | 1992-01-28 | Hoffmann-La Roche Inc. | Tetrahydronaphthalene and indane derivatives |
US4739098A (en) * | 1986-09-22 | 1988-04-19 | Allergan, Inc. | Ethynylphenyl-containing retinoic acid derivatives |
CA1305480C (en) * | 1987-03-20 | 1992-07-21 | Roshantha A.S. Chandraratna | Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity |
US5089509A (en) * | 1988-09-15 | 1992-02-18 | Allergan, Inc. | Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity |
US4810804A (en) * | 1987-03-26 | 1989-03-07 | Allergan, Inc. | Acetylenes disubstituted with a phenyl group and a heterobicyclic group having retinoid-like activity |
US4994491A (en) * | 1988-12-14 | 1991-02-19 | Molecular Design International | Dermal uses of trans-retinoids for the treatment of cancer |
KR0139216B1 (ko) * | 1988-04-11 | 1998-05-01 | 제임스 엠. 캐내지 | 레티노이드 유사활성을 갖는 페놀 또는 벤조산의 테트랄린 에스테르 |
US4895868A (en) * | 1988-06-29 | 1990-01-23 | Allergan, Inc. | Thiochroman esters of phenols and terephthallates having retinoid-like activity |
US5015658A (en) * | 1988-06-29 | 1991-05-14 | Allergan, Inc. | Thiochroman esters of phenols and terephthallates having retinoid-like activity |
AU626881B2 (en) * | 1988-07-14 | 1992-08-13 | F. Hoffmann-La Roche Ag | Benzofused heterocyclics used as pharmaceuticals |
US5049584A (en) * | 1988-12-14 | 1991-09-17 | Molecular Design International | Dermal uses of cis-retinoids for the treatment of cancer |
JPH02193990A (ja) * | 1989-01-20 | 1990-07-31 | Taisho Pharmaceut Co Ltd | チオフェンカルボン酸誘導体 |
US5068252A (en) * | 1989-07-26 | 1991-11-26 | Allergan, Inc. | Methods of using phenylethenyl compounds having retinoid-like activity |
US4992468A (en) * | 1989-07-26 | 1991-02-12 | Allergan, Inc. | Phenylethenyl compounds having retinoid-like activity |
US5183827A (en) * | 1989-09-19 | 1993-02-02 | Allergan, Inc. | Acetylenes disubstituted with a heteroaromatic group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity |
US5162546A (en) * | 1989-09-19 | 1992-11-10 | Allergan, Inc. | Acetylenes disubstituted with a phenyl group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity |
US5045551A (en) * | 1989-09-19 | 1991-09-03 | Allergan, Inc. | Acetylenes disubstituted with a heteroaromatic group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity |
US4980369A (en) * | 1989-09-19 | 1990-12-25 | Allergan, Inc. | Acetylenes disubstituted with a phenyl group and a 2-substituted chromanyl or thiochromanyl group having retinoid-like activity |
US5053523A (en) * | 1989-09-19 | 1991-10-01 | Allergan, Inc. | Ethynyl-chroman compounds |
US5023341A (en) * | 1989-09-19 | 1991-06-11 | Allergan, Inc. | Compounds having a disubstituted acetylene moiety and retinoic acid-like biological activity |
US5006550A (en) * | 1989-12-29 | 1991-04-09 | Allergan, Inc. | Chroman esters of phenols and benzoic acids having retinoid-like activity |
US5175185A (en) * | 1989-12-29 | 1992-12-29 | Allergan, Inc. | Acetylenes disubstituted with a heteroaromatic group and a substituted phenyl group having retinoid like activity |
US5013744B1 (en) * | 1989-12-29 | 1994-09-20 | Allegran Inc | Acetylenes disubstituted with a pyridinyl group and a substituted phenyl group having retinoid like activity |
US5202471A (en) * | 1990-02-06 | 1993-04-13 | Allergan, Inc. | Alkyl, alkoxy and thioalkoxy substituted diphenyl acetylenes having retinoid like activity |
US5134159A (en) * | 1991-03-26 | 1992-07-28 | Allergan, Inc. | 7-chromanyl esters of phenols and benzoic acids having retinoid-like activity |
DK0617614T3 (da) * | 1991-12-18 | 1998-09-28 | Salk Inst For Biological Studi | Midler til modulering af processer medieret af retinoide receptorer og forbindelser anvendlige dertil |
ATE256653T1 (de) * | 1992-04-22 | 2004-01-15 | Ligand Pharm Inc | Verbindungen mit retinoid x receptorselektivität |
US5324840A (en) * | 1992-06-11 | 1994-06-28 | Allergan, Inc. | Method of treatment with compounds having retinoid-like activity and reduced skin toxicity and lacking teratogenic effects |
US5455265A (en) * | 1993-02-11 | 1995-10-03 | Allergan, Inc. | Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors |
-
1993
- 1993-03-11 US US08/029,801 patent/US5399586A/en not_active Expired - Lifetime
-
1994
- 1994-03-10 AU AU64014/94A patent/AU678823B2/en not_active Ceased
- 1994-03-10 CA CA002157798A patent/CA2157798A1/en not_active Abandoned
- 1994-03-10 JP JP6520298A patent/JPH08509705A/ja not_active Ceased
- 1994-03-10 WO PCT/US1994/002577 patent/WO1994020093A1/en active IP Right Grant
- 1994-03-10 CN CN94191960A patent/CN1080117C/zh not_active Expired - Fee Related
- 1994-03-10 AT AT94911529T patent/ATE210440T1/de not_active IP Right Cessation
- 1994-03-10 DE DE69429427T patent/DE69429427T2/de not_active Expired - Fee Related
- 1994-03-10 EP EP98118824A patent/EP0909560A3/en not_active Withdrawn
- 1994-03-10 EP EP00127736A patent/EP1159961A3/en not_active Withdrawn
- 1994-03-10 EP EP94911529A patent/EP0688213B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
AU678823B2 (en) | 1997-06-12 |
EP0688213A1 (en) | 1995-12-27 |
EP1159961A2 (en) | 2001-12-05 |
DE69429427D1 (de) | 2002-01-24 |
CN1080117C (zh) | 2002-03-06 |
DE69429427T2 (de) | 2002-08-22 |
US5399586A (en) | 1995-03-21 |
ATE210440T1 (de) | 2001-12-15 |
EP0909560A2 (en) | 1999-04-21 |
AU6401494A (en) | 1994-09-26 |
WO1994020093A1 (en) | 1994-09-15 |
EP0688213B1 (en) | 2001-12-12 |
CN1122105A (zh) | 1996-05-08 |
CA2157798A1 (en) | 1994-09-15 |
EP1159961A3 (en) | 2002-05-22 |
EP0909560A3 (en) | 2002-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH08509705A (ja) | Rxrレチノイドレセプター作働剤活性を有する化合物による腫瘍の処置 | |
JPH08506816A (ja) | Rxrレチノイドレセプターに対して選択的作働剤様活性を有する化合物の医薬用途 | |
US5466861A (en) | Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors | |
CA2133587C (en) | Compounds having selectivity for retinoid x receptors | |
JP3520085B2 (ja) | レチノイド様活性を有するビニルアレーン | |
AU691477B2 (en) | Compounds having selectivity for retinoid X receptors | |
AU690772B2 (en) | Restricted 9-CIS-retinoids | |
US20060106072A1 (en) | Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors | |
JP2001505914A (ja) | レチノイド拮抗剤またはレチノイド逆作動剤型の生物学的活性を有する、アリールまたはヘテロアリール置換3,4−ジヒドロアントラセン、並びにアリールまたはヘテロアリール置換ベンゾ[1,2−g]−クロマ−3−エン、ベンゾ[1,2−g]−チオクロマ−3−エンおよびベンゾ[1,2−g]−1,2−ジヒドロキノリン誘導体 | |
CN1214675A (zh) | 具有视黄酸衍生物类生物活性的四氢萘、苯并二氢吡喃、二氢苯并噻喃和1,2,3,4-四氢喹啉羧酸的芳基或杂芳基酰胺 | |
JP2003501477A (ja) | Fxr受容体活性を調節する方法 | |
JP2002526516A (ja) | レチノイドx(rxr)受容体に選択的な活性を有する2,4−ペンタジエン酸誘導体 | |
US6043279A (en) | Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors | |
JP2002526534A (ja) | レチノイドx受容体に選択的な活性を有するテトラヒドロキノリン誘導体 | |
JP2001524099A (ja) | レチノイド作動剤、拮抗剤または逆作動剤型の生物学的活性を有する三置換フェニル誘導体 | |
JPH08333318A (ja) | RARγ特異性レチノ安息香酸誘導体 | |
PT800503E (pt) | Novos compostos retinoides trienoicos e metodos | |
US7655699B1 (en) | Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors | |
JP2003502337A (ja) | 核ホルモン受容体調節活性を有するオルガノシリル化合物 | |
US6025388A (en) | Method for inhibiting gene expression promoted by AP1 protein with RARβ selective retinoids and method for treatment of diseases and conditions with such retinoids | |
US5968908A (en) | Restricted 9-cis retinoids | |
US7019034B2 (en) | Compositions and methods for reducing serum glucose and triglyceride levels in diabetic mammals | |
US6177588B1 (en) | 1-alkoxy and 1-acyloxy substituted cyclohex-1-ene compounds and sulfur and 1-alkoxycarbonyl analogs having retinoid-like biological activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050830 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20051128 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060123 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20060410 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060523 |